Beijing Health Guard Biotechnology (BJSE:833575) LT-Debt-to-Total-Asset : 0.06 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Beijing Health Guard Biotechnology LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Beijing Health Guard Biotechnology's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.06.

Beijing Health Guard Biotechnology's long-term debt to total assets ratio increased from Sep. 2023 (0.02) to Sep. 2024 (0.06). It may suggest that Beijing Health Guard Biotechnology is progressively becoming more dependent on debt to grow their business.

Beijing Health Guard Biotechnology LT-Debt-to-Total-Asset Historical Data

The historical data trend for Beijing Health Guard Biotechnology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Health Guard Biotechnology LT-Debt-to-Total-Asset Chart

Beijing Health Guard Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.07

0.03

Beijing Health Guard Biotechnology Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.03	0.05	0.04	0.06

Beijing Health Guard Biotechnology LT-Debt-to-Total-Asset Calculation

Beijing Health Guard Biotechnology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	36.547	/	1454.292
	=	0.03

Beijing Health Guard Biotechnology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	93.433	/	1519.543
	=	0.06

Beijing Health Guard Biotechnology (BJSE:833575) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Beijing Health Guard Biotechnology LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Beijing Health Guard Biotechnology's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Health Guard Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Health Guard Biotechnology Inc (BJSE:833575) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 7 Rongchang East Street, Beijing Economic and Technological Development Zone, Room 201 and 202, Building A2, Beijing, CHN, 100176

Website

https://www.klws.com

Beijing Health Guard Biotechnology Inc engages in the research, development, and industrialization of recombinant protein vaccines. It mainly develops HPV vaccines in China and also advances multiple innovative candidate vaccines for other infectious diseases. Its core pipeline product includes a trivalent and a nonavalent HPV vaccine.

Beijing Health Guard Biotechnology Headlines

No Headlines